Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Metformin/pioglitazone (Primary)
- Indications Orofacial cancer; Oropharyngeal cancer
- Focus Therapeutic Use
- 13 Jul 2017 Planned End Date changed from 31 Mar 2019 to 10 Jun 2019.
- 13 Jul 2017 Planned primary completion date changed from 31 Mar 2019 to 10 Jun 2019.
- 13 Jul 2017 Planned initiation date changed from 15 May 2017 to 27 Dec 2017.